Global patent index - EP 1092012 A1

EP 1092012 A1 2001-04-18 - INSECT CELL ENZYMES WITH $g(a)-GALACTOSYLTRANSFERASE ACTIVITY AND THEIR USES

Title (en)

INSECT CELL ENZYMES WITH $g(a)-GALACTOSYLTRANSFERASE ACTIVITY AND THEIR USES

Title (de)

ENZYME MIT ALPHA-GALACTOSYLTRANSFERASE AKTIVITÄT VON INSEKTZELLEN, UND DEREN ANWENDUNGEN

Title (fr)

ENZYMES A ACTIVITE ALPHA-GALACTOSYLTRANSFERASE DE CELLULES D'INSECTES, ET LEURS UTILISATIONS

Publication

EP 1092012 A1 (FR)

Application

EP 99926565 A

Priority

  • FR 9901562 W
  • FR 9808228 A

Abstract (en)

[origin: FR2780413A1] Use of enzymes (I) with alpha -galactosyltransferase (aGT) activity derived from insect cells, for the enzymatic production of alpha -galactosylated compounds (II) by the transfer of galactose (Gal) on to a terminal Gal residue of a selected substrate, is new. Independent claims are also included for the following: (a) the cell line CNCM I-2045, from Mamestra brassicae; (b) cell extract with aGT, particularly alpha -1,4-aGT, activity, produced from insect cells; (c) enzymatic production of (II) by reacting UDP (uridine-diphosphate)-Gal with a substratet in presence of (I), optionally followed by purification; (d) compounds of formula (IIa); (e) pharmaceutical composition containing (IIa) and a vehicle, optionally also one or more antibiotics; and (f) food composition containing (IIa). Gal alpha 1-nGal beta 1-no-X-R (IIa) n0 = 1-4 or 6 and is the position on residue X of the carbon atom carrying a hydroxy group that binds to Gal beta 1, particularly 3 or 4; n = position of carbon atom on second Gal that carries the hydroxy group which binds to transfered Gal alpha 1; X = oside, particularly the residue of Gal, glucose (Glc), N-acetyl-D-galactosamine (GalNAc) or 2-O-acetyl-D-galactopyranose; R = hydrogen, mono- or oligo-saccharide, oside or oligoside carrying an aglycone at its reducing end, an aglycone (e.g. benzyl, phenyl (optionally substituted, particularly 4-nitrophenyl) or 1-10C alkyl, particularly 1-7C linear alkyl), glycoprotein (preferably substituted by O-glycans such as asialo-fetuin), amino acid, peptide, protein or neoglycoprotein (preferably bovine serum albumin coupled to an oligoside), glycolipid (particularly lactosylceramide or gangliosides GD3 or GM3), a lipid, a ceramide, or a multivalent non-immunogenic carrier (preferably derived from polyacrylamide or polylysine in which sidechains are substituted by Gal beta 1-n0-X).

IPC 1-7 (main, further and additional classification)

C12N 9/10; C12N 5/06; C12P 19/18; A61K 31/715; A23L 3/3562

IPC 8 full level (invention and additional information)

C12N 9/10 (2006.01); C12P 19/18 (2006.01); C12P 19/26 (2006.01)

CPC (invention and additional information)

C12N 9/1051 (2013.01); C12P 19/18 (2013.01); C12P 19/26 (2013.01); C12N 2799/026 (2013.01)

Designated contracting state (EPC)

DE FR GB IT

EPO simple patent family

FR 2780413 A1 19991231; FR 2780413 B1 20030321; AU 4376399 A 20000117; CA 2332612 A1 20000106; EP 1092012 A1 20010418; WO 0000595 A1 20000106

INPADOC legal status

2005-07-27 [18D] DEEMED TO BE WITHDRAWN

- Ref Legal Event Code: 18D

- Effective date: 20050118

2004-10-20 [17Q] FIRST EXAMINATION REPORT

- Ref Legal Event Code: 17Q

- Effective date: 20040906

2001-04-18 [17P] REQUEST FOR EXAMINATION FILED

- Ref Legal Event Code: 17P

- Effective date: 20001227

2001-04-18 [AK] DESIGNATED CONTRACTING STATES:

- Ref Legal Event Code: AK

- Designated State(s): DE FR GB IT